Is there any evidence supporting the use of GLP-1 type drugs in children and adolescents?
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
GLP-1 receptor agonists show promise in treating obesity and type 2 diabetes in adolescents 12 years and older, with modest efficacy and manageable safety profiles, though data for younger children and long-term effects are limited.
Fields of Study & Subjects
Pharmacology and Obesity Treatment
Diabetes Treatment and Management
Obesity
Physical Activity
Diet
Publication details
- Journal / source
- Zenodo (CERN European Organization for Nuclear Research)
- Publication date
- 30 March 2026
- Language
- EN